Transcend Medical Obtains $16,000,000 Series B Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c8e2579a-56a3-4368-9c63-17b74855458b&Preview=1 -
Date
7/15/2011 -
Company Name
Transcend Medical -
Mailing Address
127 Independence Drive Menlo Park, CA 94025 -
Company Description
Transcend Medical, Inc. is focused on the research and development of novel devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. Over two million people in the U.S. alone are afflicted with the disease today and the numbers are expected to grow to three million by the year 2020. The Transcend Medical approach is focused on replacing the current therapies for the treatment of glaucoma with a less invasive procedure and minimal complications. -
Website
http://www.transcendmedical.com -
Transaction Type
Venture Equity -
Transaction Amount
$16,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Transcend will use the funds for development of additional infrastructure and resources for its U.S. pivotal study of the CyPass Micro-Stent, (www.CompassClinicalStudy.com), as well as for ongoing international clinical trials and development of next generation glaucoma solutions. -
M&A Terms
-
Venture Investor
Investor Growth Capital -
Venture Investor
Canaan Partners -
Venture Investor
Latterell Venture Partners -
Venture Investor
Finistere Ventures -
Venture Investor
HLM Venture Partners -
Venture Investor
Kaiser Permanente Ventures -
Venture Investor
Morgenthaler Ventures -
Venture Investor
Split Rock Partners -
Venture Investor
Technology Partners
